CTLA4 and pancreatic neoplasm: A recent study showed that treatment with neutralizing antibodies against PD1 and CTLA4 in combination with a FAK inhibitor significantly reduced pancreatic tumor size and increased survival rates in pancreatic cancer mouse models30.